Arlene O. Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, and Vadim Koshkin, MD, University of California, San Francisco, detail the phase 2 NORSE study design, results, and implications for treating patients with metastatic urothelial carcinoma and FGFR alterations.